Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of CB-189,625 in healthy male volunteers
NL-OMON37794Phase 1Active, not recruiting
- Sponsor
- Cubist Pharmaceuticals, Inc
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute pain and chronic pain comparing CB-189,625 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Feb 2012; status: active, not recruiting.
02
Drugs
CB-189,625
03
Conditions
acute painchronic pain
Beyond the preview
Go deeper on NL-OMON37794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37794.